Allogene Therapeutics, Inc. — Form 8-K Summary
Business Context and Reporting Period
Allogene filed a current report on December 13, 2018, regarding compensation decisions reviewed on December 10 and approved by the Board on December 12, 2018. The company is an emerging growth company. The filing does not report operating results for a quarterly or annual reporting period.
Key Financial and Compensation Metrics
- David Chang, M.D., Ph.D., CEO and President: 2019 base salary increased from $525,000 to $600,000.
- Dr. Chang’s 2019 target annual cash bonus increased from 45% to 55% of base salary.
- Eric Schmidt, Ph.D., CFO: 2019 base salary increased from $375,000 to $425,000.
- Dr. Schmidt’s 2019 target annual cash bonus increased from 35% to 40% of base salary.
- Each officer was approved to receive 125% of the applicable 2018 target annual cash bonus opportunity, prorated for any partial year of service.
- Resulting 2018 cash bonus recommendations and approvals were approximately $218,000 for Dr. Chang and $88,000 for Dr. Schmidt.
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating financial metrics.
Material Changes Versus the Prior Comparable Period
- Dr. Chang’s 2019 base salary increased approximately 14.3% from 2018, and his target bonus percentage increased by 10 percentage points.
- Dr. Schmidt’s 2019 base salary increased approximately 13.3% from 2018, and his target bonus percentage increased by 5 percentage points.
- The compensation actions were described as recognition of achievements and a retention measure.
Outlook, Commentary, Risks, and Unusual Items
The Compensation Committee determined that Allogene achieved all of its 2018 corporate goals, including a stretch goal. The filing characterizes the compensation increases and bonuses as recognition of corporate and individual performance and as a retention measure. No business guidance, financial outlook, contingencies, or other material risks are disclosed.
Important Facts for Investors to Verify
- Confirm that the Board approved the stated 2019 salary and target bonus changes on December 12, 2018.
- Verify whether the approximately $218,000 and $88,000 2018 bonuses reflect prorated service periods and how they were recorded in compensation expense.
- Review subsequent filings for additional executive compensation changes, equity awards, or employment arrangements.
- Consult the company’s financial statements for operating results, cash position, liquidity, and other metrics not included in this Form 8-K.